Received Apr 28, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | — | — |
Received First Dose In 2024, and Received Second Dose; Initial report received on 16-Apr-2026. A pharmacist reported that a 30-year-old male (race and ethnicity not provided) received the first dose of HEPLISAV-B (hepatitis B vaccine) in 2024 for hepatitis B immunization and received the second dose two years later. No medical history or concomitant medications were reported. On 27-Mar-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available)]. On 16-Apr-2026, the patient received dose 2 of a hepatitis B vaccine [HEPLISAV-B (lot number 947341; expiration date 28-Mar-2028, NDC number 43528-003-05, route not available)] in the left arm. The second dose was given about two years and 18 days after the first. No adverse events were reported. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.